EGFR and non-small cell lung carcinoma: Tyrosine kinase inhibitors (TKIs) are utilized for the purpose of modulating the human EGFR activity and have emerged as the typical therapeutic approach for individuals afflicted with advanced EGFR-mutant NSCLC.